. Author manuscript; available in PMC: 2018 Aug 1.

Published in final edited form as: J Nucl Cardiol. 2016 Apr 5;24(4):1226–1235. doi: 10.1007/s12350-016-0467-6

Table 1.

Subject Characteristics

	Men	Women	p Value
N	9	10
Age (yrs)	42±3	41±3	0.86
Race (% Caucasian)	89%	60%	0.06
Body mass index (kg/m²)	31±2	35±8	0.25
Body surface area (m²)	2.12±0.08	1.89±0.08	0.07
Total cholesterol (mg/dL)	169±15	178±27	0.77
Low-density lipoprotein (mg/dL)	107±12	106±27	0.99
High-density lipoprotein (mg/dL)	37±4	53±10	0.17
Triglycerides (mg/dL)	125±41	98±12	0.48
HOMA-IR	2.55±0.51	4.40±1.77	0.35
Plasma glucose during PET (µmol/mL)	5.03±0.10	4.69±0.15	0.30
Fasting plasma FA (nmol/mL)	624±67	706±95	0.49
Fasting insulin levels (µU/mL)	10.0±2.6	22.2±8.7	0.30
Beta-blocker use	6 (67%)	8(80%)	NS
ACE-I/ARB use	9(100%)	10(100%)	NS

Data are expressed as mean ± standard error.

HOMA=homeostasis model assessment of insulin resistance; ACE-I = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; PET = Positron emission tomography